Exploring the main treatment goals and current first-line and second-line treatment options for patients with chronic GvHD.
Videos
Neal Shore, MD, FACS, reviews the case of a 75-year-old man with non-metastatic castration-resistant prostate cancer, seeks to evaluate the timeline of rising PSA to determine the aggressiveness of the disease, and considers the patient an excellent candidate for antigen receptor pathway inhibition.
Lori J. Wirth, MD, discusses the outcomes of treatment with larotrectinib for patients with NTRK fusion–positive advanced thyroid cancer.
Amer Zeidan, MBBS, explains how the approval of imetelstat may impact patients with myelodysplastic syndromes.
A medical oncologist provides a comprehensive overview of HER2-targeting agents in breast cancer and considerations to factor into treatment decisions.
Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.
Amer Zeidan, MBBS, discusses the unmet needs that exist for myelodysplastic syndromes and how imetelstat may help fill these needs.
Following a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.
A comprehensive discussion on treatment-related adverse events seen in patients receiving enfortumab vedotin and pembrolizumab.
The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.
Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss the study design and results of the EV-302 trial investigating enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma.
Amer Zeidan, MBBS, discusses how imetelstat compares with other treatments for patients with low-risk myelodysplastic syndromes with anemia who are transfusion-dependent and ineligible for erythropoiesis stimulating agents.
Daniel H. Ahn, DO, discusses how regorafenib continues to benefit patients with advanced colorectal cancer as researchers look to modify treatment strategies with the therapy.
Dr. Plimack shares her insights on some unmeet needs and challenges when treating non-clear cell renal cell carcinoma.
Lova Sun, MD, discusses genetic alterations in thyroid cancer, including RET and NTRK alterations, and how these can affect treatment options.
Amer Zeidan, MBBS, discusses imetelstat and the IMerge/MDS3001 study of the agent in patients with lower-risk myelodysplastic syndromes with anemia who are transfusion-dependent and ineligible for erythropoiesis stimulating agents.
Stephen T. Oh, MD, PhD, concludes with thoughts on the future treatment landscape for myelofibrosis.
Dr Oh discusses emerging JAK inhibitors in the myelofibrosis treatment landscape, highlighting clinical evidence that supports their use.
An overview of how toxicity concerns are balanced with the goal of achieving adequate response in patients with myelofibrosis who receive sequential therapies such as JAK inhibitors.
Stephen T. Oh, MD, PhD, discusses patients who would be suitable to receive pacritinib for myelofibrosis, highlighting data showing correlation between transfusion independence and reduction in bone marrow reticulin fibrosis.
A myelofibrosis specialist discusses his approach to monitoring treatment response in patients with myelofibrosis.
Dr Oh provides clinical insights on sequencing therapies for patients with myelofibrosis and discusses the sequential use of JAK inhibitors.
An expert on myelofibrosis discusses how to determine whether a patient is experiencing ruxolitinib failure or disease progression and provides insights on when to intervene or change therapy.
Stephen T. Oh, MD, PhD, presents the case of a 63-year-old man previously diagnosed and treated with primary myelofibrosis.
Dr. Motzer shares his viewpoint on quality-of-life preservation observed with different regimens for nccRCC patients.
Dr. Motzer discusses the risk/benefits considerations that guide decisions around continuing combination therapy with dose adjustments or stopping one agent when moderate AEs like diarrhea or liver enzyme elevations emerge in nccRCC patients on IO plus TKI regimens.
Arlene O. Siefker-Radtke, MD, dives into the background and the cohorts included in the phase 3 THOR study.
Kim N. Chi, MD, FRCPC, discusses results from the MAGNITUDE trial, including those on survival and patient-reported outcomes in patients with BRCA-positive metastatic castration-resistant prostate cancer receiving niraparib plus abiraterone acetate and prednisone.
Virginia Kaklamani, MD, DSc, explores strategies for mitigating fatigue, nausea, vomiting, and other toxicities and adverse events that may arise when patients receive endocrine therapy in combination with CDK4/6 inhibitors.
Virginia Kaklamani, MD, DSc, discusses the impact of the Phase III EMERALD trial results on the treatment landscape of HR+/HER2-low metastatic breast cancer, emphasizing the importance of selecting optimal drug combinations while minimizing toxicity profiles.